Needham & Company LLC has increased its Q1 2026 EPS estimate for Equifax to $1.69 and maintained a “Buy” rating with a $265 price target. This follows Equifax’s strong Q4 performance, beating revenue and EPS expectations, and issuing optimistic FY2026 guidance. However, a New York Times report alleging “price-gouging” by Equifax on Medicaid services introduces potential regulatory risks that could impact the stock despite positive analyst sentiment, AI expansion, and VantageScore traction.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Needham & Company LLC Lifts Earnings Estimates for Equifax
Needham & Company LLC has increased its Q1 2026 EPS estimate for Equifax to $1.69 and maintained a “Buy” rating with a $265 price target. This follows Equifax’s strong Q4 performance, beating revenue and EPS expectations, and issuing optimistic FY2026 guidance. However, a New York Times report alleging “price-gouging” by Equifax on Medicaid services introduces potential regulatory risks that could impact the stock despite positive analyst sentiment, AI expansion, and VantageScore traction.